MedTrace Logo

Can Resistance Enhance Selection of Treatment? (CREST)

NCT00262717 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 338

Last updated 2025-06-26

No results posted yet for this study

Summary

To compare two commercially available platforms for assessment of HIV drug resistance to determine which provides superior virological results.

We hypothesise that one test will be significantly superior to the other.

Conditions

  • HIV Infection

Interventions

DIAGNOSTIC_TEST

Blood test: genotype testing

Sponsors & Collaborators

Principal Investigators

  • Sean Emery, PhD · The National Centre in HIV Epidemiology and Clinical Research at the University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-01
Primary Completion
2006-01-30
Completion
2006-07-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262717 on ClinicalTrials.gov